Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2011 1
2012 1
2013 1
2014 1
2015 2
2016 4
2017 5
2018 3
2019 4
2020 5
2021 3
2022 4
2023 9
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Results by year

Filters applied: . Clear all
Page 1
Lung Cancer in Indonesia.
Asmara OD, Tenda ED, Singh G, Pitoyo CW, Rumende CM, Rajabto W, Ananda NR, Trisnawati I, Budiyono E, Thahadian HF, Boerma EC, Faisal A, Hutagaol D, Soeharto W, Radityamurti F, Marfiani E, Romadhon PZ, Kholis FN, Suryadinata H, Soeroto AY, Gondhowiardjo SA, van Geffen WH. Asmara OD, et al. Among authors: van geffen wh. J Thorac Oncol. 2023 Sep;18(9):1134-1145. doi: 10.1016/j.jtho.2023.06.010. J Thorac Oncol. 2023. PMID: 37599047 No abstract available.
ERS International Congress 2022: highlights from the Thoracic Oncology Assembly.
Catarata MJ, Van Geffen WH, Banka R, Ferraz B, Sidhu C, Carew A, Viola L, Gijtenbeek R, Hardavella G. Catarata MJ, et al. Among authors: van geffen wh. ERJ Open Res. 2023 Aug 14;9(4):00579-2022. doi: 10.1183/23120541.00579-2022. eCollection 2023 Jul. ERJ Open Res. 2023. PMID: 37583965 Free PMC article.
Best first-line therapy for people with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status.
Gijtenbeek RG, de Jong K, Venmans BJ, van Vollenhoven FH, Ten Brinke A, Van der Wekken AJ, van Geffen WH. Gijtenbeek RG, et al. Among authors: van geffen wh. Cochrane Database Syst Rev. 2023 Jul 7;7(7):CD013382. doi: 10.1002/14651858.CD013382.pub2. Cochrane Database Syst Rev. 2023. PMID: 37419867
Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry study.
Gijtenbeek RGP, Damhuis RAM, van der Wekken AJ, Hendriks LEL, Groen HJM, van Geffen WH. Gijtenbeek RGP, et al. Among authors: van geffen wh. Lancet Reg Health Eur. 2023 Feb 6;27:100592. doi: 10.1016/j.lanepe.2023.100592. eCollection 2023 Apr. Lancet Reg Health Eur. 2023. PMID: 36817181 Free PMC article.
Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer.
Gijtenbeek RGP, van der Noort V, Aerts JGJV, Staal-van den Brekel JA, Smit EF, Krouwels FH, Wilschut FA, Hiltermann TJN, Timens W, Schuuring E, Janssen JDJ, Goosens M, van den Berg PM, de Langen AJ, Stigt JA, van den Borne BEEM, Groen HJM, van Geffen WH, van der Wekken AJ. Gijtenbeek RGP, et al. Among authors: van geffen wh. ERJ Open Res. 2022 Oct 17;8(4):00239-2022. doi: 10.1183/23120541.00239-2022. eCollection 2022 Oct. ERJ Open Res. 2022. PMID: 36267895 Free PMC article.
40 results